Lindo and Airbus Collaborate on Antimicrobial Blue Light for HEMS

This article is based on an official press release from Lindo.

Lindo has officially announced a new collaboration with Airbus Asia Pacific and Airbus Helicopters, marked by the signing of a Memorandum of Understanding (MoU). The agreement centers on the exploration and development of antimicrobial blue light (aBL) applications specifically designed for Helicopter Emergency Medical Services (HEMS).

According to the official statement released by Lindo, this partnership establishes a strategic framework to investigate the integration of occupant-safe disinfection technologies into next-generation aeromedical platforms. The initiative is positioned to support future HEMS programs throughout Australia and the broader Asia Pacific region.

At the heart of this collaboration is a focus on infection prevention. Critical care transport environments operate under intense time pressures and experience high patient turnover, creating inherent risks for pathogen transmission that both companies are now seeking to mitigate.

Advancing Aeromedical Disinfection Technology

Helicopter Emergency Medical Services face unique operational challenges. The confined spaces of aeromedical cabins require rigorous cleaning protocols between missions, which can impact turnaround times and operational efficiency. By introducing antimicrobial blue light technology, Lindo and Airbus aim to provide a continuous, autonomous layer of protection.

In their public announcement, Lindo emphasized the operational and safety benefits of this technological leap for healthcare transport environments.

“Advancing autonomous, continuous disinfection within these settings represents a meaningful step toward reducing pathogen transmission while maintaining operational efficiency,” stated Lindo in their official release.

Research, Development, and Future Integration

Phased Approach to Certification

The collaboration will initially prioritize research and development. According to the company’s statement, the early phases of the project will focus on feasibility studies, system integration, and the rigorous validation of antimicrobial lighting solutions within Airbus helicopter platforms.

Following the successful completion of these R&D milestones, the partnership intends to map out potential pathways for certified integration into operational aircraft, ensuring the technology meets stringent aviation safety and regulatory standards.

Collaborative Innovation and Support

This MoU represents a significant alignment of global aerospace capabilities with Australian technological innovation. The technical execution from Lindo’s side is being driven by their internal R&D team, including Urbain du Plessis, in conjunction with their design partners at Marker Design.

The initiative has also garnered regional backing. Lindo acknowledged the continued support of the Victorian Government in enabling advanced manufacturing and technology development within the state. The company publicly thanked key government representatives, including Gönül Serbest, Teresa Tufano, and Chin Wijesuriya, alongside Airbus personnel Christian Venzal, Scott White, Andrew Wild, Richard Ward, and Mandy Hentschel for their roles in supporting the MoU.

AirPro News analysis

We view this MoU as a highly relevant development in the evolution of aeromedical transport. The global healthcare sector has placed an increased premium on passive, continuous disinfection technologies in the wake of recent global health challenges. Antimicrobial blue light (aBL) is particularly notable because, unlike traditional UV-C light, specific wavelengths of aBL can be deployed safely in the presence of human occupants. If Lindo and Airbus successfully navigate the complex aviation certification pathways, this technology could establish a new baseline for cabin safety and infection control in future HEMS fleets worldwide.

Frequently Asked Questions (FAQ)

What is the primary focus of the Lindo and Airbus MoU?
The agreement focuses on exploring and integrating antimicrobial blue light (aBL) disinfection applications into Helicopter Emergency Medical Services (HEMS).

Which regions will benefit from this collaboration?
The framework is designed to support future HEMS programs across Australia and the broader Asia Pacific region.

Who is involved in the research and development?
The R&D is being led by Lindo’s internal team and Marker Design, with integration support from Airbus Helicopters and advanced manufacturing backing from the Victorian Government.

Sources

• Lindo Official Statement